Accumulating evidence has shown that drug-target interactions (Dtis) play a crucial role in the process of genomic drug discovery. Although biological experimental technology has made great progress, the identification of DTIs is still very time-consuming and expensive nowadays. Hence it is urgent to develop in silico model as a supplement to the biological experiments to predict the potential Dtis. In this work, a new model is designed to predict DTIs by incorporating chemical sub-structures and protein evolutionary information. Specifically, we first use Position-Specific Scoring Matrix (PSSM) to convert the protein sequence into the numerical descriptor containing biological evolutionary information, then use Discrete Cosine Transform (DCT) algorithm to extract the hidden features and integrate them with the chemical sub-structures descriptor, and finally utilize Rotation Forest (RF) classifier to accurately predict whether there is interaction between the drug and the target protein. In the 5-fold cross-validation (CV) experiment, the average accuracy of the proposed model on the benchmark datasets of Enzymes, Ion Channels, GPCRs and Nuclear Receptors reached 0.9140, 0.8919, 0.8724 and 0.8111, respectively. In order to fully evaluate the performance of the proposed model, we compare it with different feature extraction model, classifier model, and other state-of-the-art models. Furthermore, we also implemented case studies. As a result, 8 of the top 10 drug-target pairs with the highest prediction score were confirmed by related databases. These excellent results indicate that the proposed model has outstanding ability in predicting Dtis and can provide reliable candidates for biological experiments. Drugs can regulate the physiological function of the human body, to provide guarantee for disease prevention, treatment and other aspects. More importantly, the discovery and identification of drug targets is the source of drug research, which plays a key role in the success of drug development. The complexity of the etiologies of most diseases leading to disease-related genes or proteins may be potential drug targets, but because of target specificity, robustness of biological networks and other factors, the number of newly developed drugs does not rapidly increase with the development of proteomics and chemical genomics. So far, only a small number of targets in the human genome, in which the total number of pharmacological interest is about 6000 to 8000, have been confirmed to be associated with approved drugs 1-4. As the experiment-based method having the disadvantage of high cost, time consuming and limitations of small-scale in identifying drug-target interactions, researchers try to mine drug-related targets in the whole genome using computational-based methods 5-11. At present, researchers have designed many computational-based models to analyze and predict drug-target interactions (DTIs) 12-18. For example, Yamanishi et al. designed a model based on statistical algorithm to predict potential DTIs, which ...